Article Text

Download PDFPDF
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition
  1. Kari L. Ring, MD,
  2. Melinda S. Yates, PhD,
  3. Rosemarie Schmandt, PhD,
  4. Michaela Onstad, MD,
  5. Qian Zhang, PhD,
  6. Joseph Celestino, BS,
  7. Suet-Ying Kwan, BS and
  8. Karen H. Lu, MD
  1. Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
  1. Address correspondence and reprint requests to Karen H. Lu, MD, Department of Gynecologic Oncology and Reproductive Medicine, 1155 Hermann Pressler Dr, Unit 1362 Houston, TX 77030. E-mail: khlu@mdanderson.org.

Abstract

Objectives The aims of this study were to determine if activating KRas mutation alters estrogen signaling in endometrial cancer (EC) and to explore the potential therapeutic impact of these alterations.

Methods The Cancer Genome Atlas was queried for changes in estrogen-regulated genes in EC based on KRas mutation status. In vitro studies were conducted to evaluate estrogen receptor α (ERα) phosphorylation changes and related kinase changes in KRas mutant EC cells. The resulting effect on response to MEK inhibition, using trametinib, was evaluated. Immunohistochemistry was performed on KRas mutant and wild-type EC tumors to test estrogen signaling differences.

Results KRas mutant tumors in The Cancer Genome Atlas showed decreased progesterone receptor expression (P = 0.047). Protein analysis in KRas mutant EC cells also showed decreased expression of ERα (P < 0.001) and progesterone receptor (P = 0.001). Although total ERα is decreased in KRas mutant cells, phospho-ERα S118 was increased compared with wild type. Treatment with trametinib in KRas mutant cells increased phospho-ERα S167 and increased expression of estrogen-regulated genes. While MEK inhibition blocked estradiol-stimulated phosphorylation of ERK1/2 and p90RSK in wild-type cells, phospho-ERK1/2 and phospho-p90RSK were substantially increased in KRas mutants. KRas mutant EC tumor specimens showed similar changes, with increased phospho-ERα S118 and phospho-ERα S167 compared with wild-type EC tumors.

Conclusions MEK inhibition in KRas mutant cells results in activation of ER signaling and prevents the abrogation of signaling through ERK1/2 and p90RSK that is achieved in KRas wild-type EC cells. Combination therapy with MEK inhibition plus antiestrogen therapy may be necessary to improve response rates in patients with KRas mutant EC.

  • Endometrial cancer
  • Estrogen signaling
  • KRas
  • MEK inhibitor

Statistics from Altmetric.com

Footnotes

  • This work was supported by the M. D. Anderson Uterine Cancer SPORE (NIH P50CA098258 to K.H.L.), a T32 training grant for gynecologic oncology (NIH CA101642 to K.H.L.), and by the M. D. Anderson Cancer Center support grant (NIH CA016672) that supports the Sequencing and Microarray Core Facility, the Functional Proteomics Reverse Phase Protein Array (RPPA) Core, Biostatistics and Bioinformatics Resource Groups, and the Flow Cytometry and Cellular Imaging Facility.

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.